News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

InflaRx (NASDAQ: IFRX) had its price target raised by analysts at Guggenheim from $7.00 to $10.00. They now have a "buy" rating on the stock.

InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting [Yahoo! Finance]

11/8/2024

07:30 am

ifrx

2.0%

MISS

8/8/2024

07:30 am

ifrx

-5.0%

MISS

5/8/2024

07:30 am

ifrx

0.0%

BEAT

Form 6-K InflaRx N.V. For: Apr 03

Form 20-F InflaRx N.V. For: Dec 31

Form 6-K InflaRx N.V. For: Mar 20

Form 6-K InflaRx N.V. For: Feb 18

Form 424B5 InflaRx N.V.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}